Daily closing price · 250 sessions
Quantitative price outlook based on available market signals. Not financial advice.
Indicators calculated from the stored daily price history.
A verified, data-driven analysis will be generated here from price action, technical indicators, fundamentals, earnings and market context.
Dedicated research sections for 2026, 2030, 2035, 2040 and 2050. Numerical targets will appear only after the long-horizon model is validated.
Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2026 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2030 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2035 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2040 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2050 research →Only stories explicitly associated with this stock are shown.
Hims & Hers Health has reached a three million member milestone and has doubled in value over six months. The article examines whether the stock remains a good investment opportunity in September 2026, with one analyst predicting a 56% gain by year-end. Recent insider stock disposals and the company's expansion into testosterone and peptides are also noted.
Hims & Hers Health faces a securities fraud class action lawsuit after the FTC alleged the telehealth provider shared consumers' sensitive health information with third-party advertising platforms while claiming privacy protection, and deceived users about billing and cancellation practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased securities between August 4, 2025 and July 29, 2026 can file lead plaintiff applications by November 2, 2026.
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) for allegedly making materially false statements about its privacy practices. The FTC accused HIMS of sharing customers' medical information with third-party advertisers including Meta and Snap. Following the FTC lawsuit announcement on July 29, 2026, HIMS stock declined 14.73%. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 can seek lead plaintiff status by November 2, 2026.
A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false statements and failing to disclose that it shares consumers' health information with third-party advertising platforms and charges for prescriptions immediately after intake forms are submitted. The FTC, California, and Utah filed a separate lawsuit on July 29, 2026, alleging deceptive practices including difficult subscription cancellations and misleading privacy claims. The stock fell 14.73% following the FTC action.
A securities class action has been filed against Hims & Hers Health, Inc. following FTC allegations that the company failed to disclose immediate prescription charges, made it difficult for consumers to cancel subscriptions, and shared health information with third-party advertising platforms without proper consent. The stock fell 14.73% on July 29, 2026, following the FTC lawsuit announcement.
Common questions about price, predictions, long-term forecasts, technicals and research methodology.
HIMS is currently shown at $28.00 in the latest stored market quote. The page is refreshed from the connected market-data pipeline.
A quantitative forecast is not currently available for HIMS.
The 2026 long-term forecast section is included as a research framework. A numerical 2026 target is shown only after a dedicated long-horizon model has produced and validated it; the current 24H–90D model is not presented as a 2026 target.
The 2030 section tracks the inputs that a validated long-horizon model should use, including company growth, valuation, earnings, market regime and sector conditions. No unsupported price target is displayed.
The 2035, 2040 and 2050 sections are reserved for long-term model outputs. US Market AI does not invent numerical targets when validated long-horizon data is unavailable.
The page can display RSI, MACD, SMA 50, SMA 200, EMA 20, ATR, ADX, volatility, Bollinger levels, stochastic, support and resistance from stored daily price history.
Fundamental data is not currently populated for this stock, so the page does not estimate or fabricate missing values.
The latest ticker-linked news appears in the Market News section of this page. Stories are shown with source, publication date and sentiment when available.
There is not yet enough mature evaluation data on this page to claim a verified accuracy rate.
No. US Market AI provides research and model estimates for informational purposes. Forecasts can be wrong and should not be treated as personalized financial advice.
US Market AI combines quantitative signals and verified market data to support research. Forecasts are estimates, can be wrong, and are not financial advice.